Tasso, maker of a device for at-home blood collection, has raised $100 million in Series B financing.

The round was led by RA Capital Management, with participation from the D.E. Shaw group, Senvest, InCube, SVB Innovation Fund, Foresite Capital, Hambrecht Ducera Growth Ventures, J2V, Cedars-Sinai and Merck GHIF.

The latest financing builds upon a $17 million Series A from last year and a $6.1 million round in 2019. The company plans to use the influx of capital to build up its manufacturing and operations to meet demand for its blood collection devices. 

“With the COVID-19 pandemic, there has been a fundamental shift in how we think about healthcare, and demand for patient-centric, in-home solutions is greater than ever,” Tasso CEO and cofounder Ben Casavant said in a statement.

“Today, Tasso devices are successfully supporting decentralized clinical trials, clinical research and remote patient health monitoring. This funding round validates the success of our efforts to date, and will increase streamlined access to home diagnostics for everyone in the future.”

Weight loss startup Found also scooped up $100 million in Series B funding, bringing its valuation to $600 million, according to TechCrunch. 

The round was led by WestCap, with participation from IVP, the Chernin Group, G9 Ventures and Able Partners, alongside existing and angel investors. 

The company emerged from stealth earlier this year, announcing it had raised $32 million since its launch in 2020. That funding was made up of a $24 million Series A and an $8 million seed round.

Well Dot, a digital health platform that uses AI to motivate users to achieve goals and navigate their benefits, raised $70 million in a Series B round led by Valeas Capital Partners.

In 2020, the company scooped up $40 million in Series A funding, and it raised $25 million in seed funding in 2019. The company plans to use Series B to scale operations and improve its platform.

Digital dental care company Overjet scored $42.5 million in a Series B funding round led by General Catalyst and Insight Partners. 

The round, which also included participation from existing investors Crosslink Capital and E14 Fund, brings the company’s valuation to $425 million. It comes just months after Overjet raised $27 million in Series A funding, clocking in the dental-health startup’s total financing at almost $80 million.

"Overjet's cutting-edge software has seen incredible demand from clinicians and insurers alike who see our dental AI as a transformational technology to advance patient oral healthcare," CEO and cofounder Wardah Inam said in a statement.

"The new financing will accelerate our next chapter of growth to support our customers, grow the team and invest in the next generation of technology to support patient care."

AI-backed fertility counseling company Univfy raised $6 million in a Series B round led by  a portfolio company of Atlantic Street Capital.

The company raised another $6 million in Series A funding in 2018. It plans to use the new capital to offer its platform to employers and health plans as a benefit for understanding the success of potential fertility treatment and its costs. 

"We are very excited to be working with Univfy, whose vision to help fertility centers achieve better clinical outcomes aligns with ours," Ashish Shetty, principal of Atlantic Street Capital, said in a statement.

"Univfy is the leader in using AI/ML to improve fertility patients' experience and maximize each patient's chances of having a baby with fertility treatment. We are honored to be a partner in helping to bring the benefits of Univfy's AI/ML technology to more patients and providers."

Marigold Health, which offers an AI-supported peer support chat for people with substance abuse disorders and other mental health issues, raised $3.5 million in seed funding.

The round included investments from Tau Ventures, KdT, Epsilon, Flare and Felicis.

“The power to peer model means Marigold relies on natural language processing (NLP) to understand intent. They also rely on two main channels: bulk outreach through payers (insurers) and outpatient referrals through local providers (doctors),” Tau Ventures managing partner Amit Garg wrote on LinkedIn. 

“The company’s vision is that, by preventing or minimizing addiction at a population level, they can significantly save costs, to the level of 20x, and obviously improve people’s lives.”